Get the Stockscreener App
2.84
11.37%
0.29
After Hours:
2.27
-0.57
-20.07%
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock -March 19, 2025 at 10:18 pm EDT - Marketscreener.com
Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - StockTitan
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire Inc.
Akebia Therapeutics launches public stock offering By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Akebia Therapeutics Inc. - Quantisnow
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Akebia Therapeutics announces proposed public offering of common stock -March 19, 2025 at 04:57 pm EDT - Marketscreener.com
Akebia Therapeutics launches public stock offering - Investing.com
Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game? - Insider Monkey
Akebia Therapeutics dives on stock offering plans - TradingView
Akebia Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Unveils Major Public Offering: Key Details for Investors - StockTitan
AKBA stock touches 52-week high at $2.48 amid robust gains - Investing.com Australia
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Akebia slumps after Q4 earnings miss - MSN
H.C. Wainwright maintains Akebia stock Buy rating, $7.50 target By Investing.com - Investing.com Canada
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83 - Simply Wall St
US$7.83That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results - Yahoo Finance
Piper Sandler raises Akebia stock target to $6 on Vafseo launch - Investing.com Canada
Akebia Therapeutics Inc (AKBA): Navigating Revenue Declines and Unlocking Growth Potential - RagingBull
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ... - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Akebia Therapeutics Reports Progress in Vafseo Launch - TipRanks
Akebia Therapeutics: Q4 Earnings Snapshot - mySA
Sector Update: Health Care Stocks Slipping Late Afternoon -March 13, 2025 at 04:07 pm EDT - Marketscreener.com
Sector Update: Health Care -March 13, 2025 at 03:44 pm EDT - Marketscreener.com
Akebia Therapeutics Shares Fall After Q4 Results -March 13, 2025 at 02:52 pm EDT - Marketscreener.com
Akebia stock slumps after Q4 earnings miss (AKBA:NASDAQ) - Seeking Alpha
Akebia Therapeutics Reports Fourth Quarter and Full Year - GlobeNewswire
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: Akebia Therapeutics Q4 2024 misses EPS forecasts By Investing.com - Investing.com UK
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Akebia Therapeutics, Inc. SEC 10-K Report - TradingView
AKEBIA THERAPEUTICS Earnings Results: $AKBA Reports Quarterly Earnings - Nasdaq
Akebia's New Drug Vafseo Captures Entire US Dialysis Market, Projects $11M Q1 Revenue - StockTitan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Thinking about buying stock in VinFast Auto, Akebia Therapeutics - GuruFocus.com
AKEBIA THERAPEUTICS Earnings Preview: Recent $AKBA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Exploring High Growth Tech Stocks In The US Market - Simply Wall St
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Increased by Rhumbline Advisers - Defense World
Akebia Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Akebia Therapeutics, Inc. Scheduled to Report Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights - The Manila Times
Akebia Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
When Will Akebia Report Q4 Earnings? Key Date for Biotech Investors - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World
Akebia Therapeutics (AKBA) to Release Earnings on Thursday - Defense World
Akebia Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Issues 13,525 Stock Options: What This Means for Shareholder Dilution - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Upgraded by StockNews.com - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA investor five-year losses grow to 80% as the stock sheds US$55m this past week - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) Cut to Sell at StockNews.com - Defense World
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 19.7% - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at StockNews.com - MarketBeat
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):